The shift is primarily driven by the pursuit of patient-centric treatment. Oral delivery improves patient adherence and acceptance by eliminating painful injections, particularly for chronic conditions requiring long-term management. Additionally, the move toward decentralized healthcare and self-administration supports the demand for convenient oral formats.
Type II diabetes is the largest indication due to its high global disease burden (over 500 million people) and the strong patient preference for non-invasive treatments. The development of oral semaglutide and oral insulin candidates has positioned this segment at the forefront of the industry.
Peptides currently lead the market because of their relatively smaller molecular size compared to proteins, which allows for improved absorption. Their dominance is further supported by the successful adoption of oral GLP-1 analogues for metabolic diseases and advancements in mucoadhesive tablets that enhance peptide stability.
The industry is utilizing advanced delivery platforms including enteric coatings, protease inhibitors, pH-responsive systems, and encapsulation. Furthermore, "smart" delivery mechanisms like robotic pills (e.g., RaniPill) and autonomous capsules with microneedles are being developed to ensure biologics survive the harsh gastrointestinal environment.
North America holds the largest market share, centered largely in the United States. This leadership is attributed to a robust R&D pipeline, high clinical trial activity, presence of major players like Amgen and Oramed, and a favorable regulatory environment facilitated by the FDA.
The Asia-Pacific region is anticipated to advance most rapidly. This growth is fueled by a heavy chronic disease burden (particularly diabetes), improving biotechnological infrastructure in India, China, and South Korea, and increased government investment in drug delivery innovation.
Key developments include Novo Nordisk’s expanded trials for oral semaglutide (October 2024), Oramed Pharmaceuticals receiving FDA fast-track status for its Phase III oral insulin candidate ORMD-0801 (August 2024), and Rani Therapeutics reporting positive Phase II data for its oral parathyroid hormone (January 2023).
The primary obstacles include low bioavailability and the inherent instability of large molecules in the gastrointestinal tract. Additionally, the high cost and complexity of formulation, rigorous regulatory scrutiny for novel delivery mechanisms, and technical difficulties in scaled manufacturing pose significant hurdles.
The market features a mix of big pharmaceutical companies and specialized biotech firms, including Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Eli Lilly and Company, Biocon Limited, Pfizer Inc., Rani Therapeutics, Entera Bio Ltd., and Protagonist Therapeutics.
